Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current HIV clinical trial design issues

J M Lange1

  • 1Department of Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands.

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An experimental investigation of the effect of a justice violation on pain experience and expression among individuals with high and low just world beliefs.

European journal of pain (London, England)·2013
Same author

[The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].

Nederlands tijdschrift voor geneeskunde·2006
Same author

Adequacy of peritoneal dialysis and the importance of preserving residual renal function.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2006
Same author

[Coinfection with hepatitis C virus and HIV].

Nederlands tijdschrift voor geneeskunde·2003
Same author

Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.

Antiviral therapy·2002
Same author

Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine.

Therapeutic drug monitoring·2002
Same journal

Mortality risk in selenium-deficient HIV-positive children.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association·1999
Same journal

Predictors and risk-taking consequences of drug use among HIV-infected women.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association·1999
Same journal

Correlates of condom failure in a sexually active cohort of men who have sex with men.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association·1999
Same journal

Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association·1999
Same journal

Predominance of CCR5-dependent HIV-1 subtype E isolates in Cambodia.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association·1999
Same journal

Protease inhibitor use among a community sample of people with HIV disease.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association·1999
See all related articles

Clinical trials for HIV treatments need new markers beyond traditional endpoints. Viral load is a promising marker for demonstrating antiretroviral drug efficacy, especially with combination therapy.

Area of Science:

  • Infectious Diseases
  • Clinical Pharmacology
  • Virology

Background:

  • Increased survival in HIV patients necessitates novel clinical trial endpoints beyond traditional hard endpoints like AIDS progression or death.
  • Challenges in current HIV clinical trials include long study durations, patient retention, and prophylaxis preventing traditional endpoints.
  • Early treatment initiation in HIV infection further complicates the use of hard clinical endpoints for demonstrating antiretroviral efficacy.

Purpose of the Study:

  • To evaluate the suitability of "soft" clinical and laboratory endpoints, such as CD4 cell count decline, for demonstrating antiretroviral efficacy.
  • To highlight the need for accurate markers of disease progression in current HIV clinical trials.
  • To advocate for viral load as a primary endpoint in antiviral drug studies, focusing on the drug's effect on the virus itself.

Related Experiment Videos

Main Methods:

  • Review of historical clinical trial methodologies and the introduction of "soft" endpoints in study EACG 020.
  • Discussion of the quantification of viral burden in various tissues.
  • Emphasis on the necessity of profound and long-term viral load reduction for validation.

Main Results:

  • The use of "soft" endpoints like CD4 cell count decline enabled the demonstration of zidovudine (AZT) efficacy in early-stage HIV infection.
  • Viral load quantification is now possible, offering a direct measure of antiviral effect.
  • Profound and sustained viral load reduction is likely achievable with early-stage combination therapy.

Conclusions:

  • Viral load is a critical and validated marker for assessing antiretroviral drug efficacy, particularly in combination therapy.
  • Clinical trials are essential to further validate viral load as a primary endpoint.
  • Regulatory authorities should consider licensing drugs based on viral load data, coupled with post-licensing follow-up.